Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2011-07-11 Regulatory Filings
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Clinical Trial Update 2 pages 172.7KB
Regulatory Filings Classification · 95% confidence The document is a clinical trial update from CBio Limited, providing preliminary data on a phase IIa clinical trial for a drug candidate. It is addressed to the ASX Company Announcements Office and contains no financial statements, regulatory certifications, or detailed financial data. The document is relatively short (3160 characters) and serves as an announcement of clinical trial progress rather than a financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The content is an update on clinical trial progress, which is a form of general regulatory announcement to the market. Given the lack of financial data and the nature of the announcement, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2011-07-11 English
Appendix 3B 8 pages 478.8KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number and class of securities, issue price, purpose of the issue, and quotation application to the ASX. It is a regulatory form used in Australian securities markets to announce new share issues and related details. The content focuses on the announcement and application for quotation of additional securities rather than a full financial report or earnings release. It does not contain financial statements or management discussion but is a formal announcement of capital changes. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is substantial and contains detailed issuance information, supporting a high confidence in classification.
2011-07-06 English
Section 708A Notice 2 pages 201.3KB
Capital/Financing Update Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 regarding the issuance of shares and share options by CBio Limited. It provides legal compliance statements about the issuance without disclosure under Part 6D.2 of the Corporations Act. The document is short (3,588 characters) and primarily serves as a regulatory announcement about a capital raising event (issuance of shares and options). It does not contain financial statements, detailed financial analysis, or management discussion. It is not a full report but a formal notification of a capital transaction. Therefore, it fits best under Capital/Financing Update (CAP).
2011-07-06 English
Appendix 3B 11 pages 654.1KB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the issuance of a convertible note by CBio Limited, including an Appendix 3B form which is a standard ASX (Australian Securities Exchange) form for new issue announcements and applications for quotation of additional securities. The content focuses on the terms of the convertible note, the number and class of securities issued, and compliance with ASX listing rules. There is no financial statement or comprehensive financial analysis present, nor is this a report or presentation. The document is clearly an announcement of a capital raising event and issuance of securities, specifically convertible notes, under a funding facility. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief report publication announcement or a regulatory filing. Confidence is high due to the explicit mention of convertible note issuance and Appendix 3B form, which is used for capital raising disclosures.
2011-07-05 English
Response to ASX Price Query 5 pages 209.9KB
Regulatory Filings Classification · 95% confidence The document is a formal response letter from CBio Limited to ASX Compliance Pty Limited regarding a price query about the company's share price movement and trading volume. It addresses questions about undisclosed information, financial performance expectations, and compliance with listing rules. The content is a regulatory compliance communication related to stock price movements and disclosure obligations, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data but is a regulatory filing responding to a market query. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length (9581 characters) and detailed Q&A format support this classification rather than a brief announcement or a full report.
2011-07-03 English
Notice of Conversion of Notes 2 pages 164.8KB
Capital/Financing Update Classification · 100% confidence The document is a notice from CBio Limited to the ASX regarding the conversion of convertible notes into shares and options. It details the number of notes converted, the resulting shares and options issued, and the remaining convertible notes on issue. The document is a formal announcement about a capital structure change involving convertible notes converting into equity. It does not contain financial statements, management discussion, or detailed financial results. It is not an annual or interim report, nor an earnings release or audit report. The content fits the category of a Capital/Financing Update, as it informs about a financing activity (conversion of notes into shares and options). The document length is 3754 characters, which is consistent with a concise announcement rather than a full report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2011-06-30 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.